Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Philip J SmithLisa CritchleyDaniel StoreyBelle GreggJune StensonAndrew KneeboneTracy RimmerStevena BurkeShamas HussainWan Yi TeohStephan VazeilleSolange SernaAlan SteelEdmund DerbyshirePaul CollinsMartyn DibbPaul FlanaganChristopher Sj ProbertAjay Mark VermaSreedhar SubramanianPublished in: Journal of Crohn's & colitis (2022)
Among patients on IV infliximab maintenance therapy switched to SC CT-P13, we observed high treatment persistence rates and low rates of immunogenicity, with no change in clinical disease activity indices or biomarkers. Infliximab levels increased after switch to SC CT-P13, and only ATI was associated with serum infliximab levels. Patient acceptance and satisfaction rates were high with SC CT-P13.
Keyphrases
- image quality
- dual energy
- disease activity
- computed tomography
- contrast enhanced
- ulcerative colitis
- rheumatoid arthritis
- systemic lupus erythematosus
- positron emission tomography
- rheumatoid arthritis patients
- magnetic resonance imaging
- clinical trial
- ankylosing spondylitis
- magnetic resonance
- stem cells
- study protocol
- high dose
- randomized controlled trial
- cross sectional
- juvenile idiopathic arthritis